Search Results
Nov 03, 2025, 13:31 ET Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting
in the treatment of patients with CAD or CAS; and a prospective evaluation of siltuximab in the prevention or treatment of cytokine release syndrome (CRS) after CAR T-cell therapy.
More news about: Recordati
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
No dose-limiting toxicities (DLT), treatment discontinuations, or deaths were observed. Four patients experienced Grade 1 cytokine release syndrome (CRS), all of which resolved within 2-10 days. Previously, in October 2025, CARsgen announced preliminary clinical data for CT0596
More news about: CARsgen Therapeutics
Nov 03, 2025, 09:00 ET Cowbell Unveils Brand Refresh: The Sound Approach to Risk for the New AI Era
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions,
More news about: Cowbell Cyber, Inc.
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
received at least one prior line of systemic therapy. Results from the study demonstrated that the incidence and severity of cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) following treatment with epcoritamab were consistent with previous epcoritamab studies in
More news about: AbbVie
Oct 30, 2025, 05:00 ET IBS Software Appoints Abha Dogra as Chief Product Officer
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Oct 28, 2025, 19:00 ET PTS to Launch Japan-Origin Bitcoin Mining Investment Product via Republic Platform Under U.S. Regulation
and Form CRS
More news about: Pivotal Trend Service Co., Ltd.
Oct 28, 2025, 19:00 ET PTS to Launch Japan-Origin Bitcoin Mining Investment Product via Republic Platform Under U.S. Regulation
and Form CRS
More news about: Pivotal Trend Service Co., Ltd.
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
achieving complete remission after other treatments have failed. Nonetheless, CAR-T therapy carries potential risks, including Cytokine Release Syndrome (CRS) and neurological side effects, requiring vigilant monitoring by trained healthcare professionals throughout the treatment process.
More news about: DelveInsight Business Research, LLP
Oct 28, 2025, 05:00 ET Thai Airways invests in Digital Loyalty Transformation with IBS Software's iLoyal Platform
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Oct 27, 2025, 18:21 ET Taxbit Appoints Former OECD Advisor Colby Mangels as Global Head of Government Solutions
leading role in developing the Crypto-Asset Reporting Framework (CARF) and the most recent amendments to the Common Reporting Standard (CRS), as well as in leading peer reviews of jurisdictions' compliance with these international transparency standards. He also contributed to the Financial
More news about: Taxbit
Oct 26, 2025, 21:00 ET Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy.
More news about: Antengene Corporation Limited
Oct 23, 2025, 09:00 ET Cowbell Announces Strategic Appointments to Advance Mid-Market and Claims Leadership
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions
More news about: Cowbell Cyber, Inc.
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
respectively. Safety: Cytokine release syndrome (CRS) occurred in 88.9% of patients, primarily grade 1-2. Only one patient developed grade 3 or higher CRS, which rapidly recovered with intensive management. One patient developed grade 3 immune effector
More news about: IASO Bio
Oct 20, 2025, 20:33 ET MTC, ABAG Release Draft of New Long-Range Plan for Bay Area
al (415) 778-6757. Para telecomunicaciones para personas sordas y discapacitadas, favor de llamar al 711, el Servicio de Retransmisión de California (CRS) para TTY/VCO/HCO a Voz o para Voz a TTY/VCO/HCO al (800) 855-3000 y pedir que lo retrasmitan al (415) 778-6700. 您是否需要口譯或任何其他
More news about: Metropolitan Transportation Commission
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
demonstrated durable response and has been on the study for over 22 months. To date, the study has observed three CRs, one from each of the three forementioned cohorts (two dose cohorts among CLDN18.2 mid/high expressors and the cohort of low/ultra low CLDN18.2 expressors).
More news about: Antengene Corporation Limited
Oct 19, 2025, 20:15 ET CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
51.3% to 96.1%. All patients developed Grade 1 or 2 cytokine release syndrome (CRS) after the first satri-cel infusion. For the second infusion administered in one patient, grade 3 CRS accompanied by hypotension was observed, which was resolved within three days following tocilizumab
More news about: CARsgen Therapeutics
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
(proteasome inhibitor, immunomodulatory agent, and CD38 monoclonal antibody). The patient developed Grade 1 CRS, Grade 4 neutropenia, and thrombocytopenia following lymphodepletion and CAR-T cell infusion. The CRS and cytopenias were resolved after treatment with tocilizumab and other supportive measures. CAR-T
More news about: CARsgen Therapeutics
Oct 17, 2025, 03:48 ET Marengo Asia Hospitals acquires majority stake in 350-bed Sunshine Global Hospitals
Havells and Godrej family offices and Dr Raajiv Singhal and is one of the fastest growing unlisted hospital chains with a revenue run-rate of ~ INR 1,200crs p.a. Photo:
More news about: Marengo Asia Hospitals
Oct 16, 2025, 08:45 ET Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
new/enlarging T2 lesions. Manageable safety profile: Only transient grade 1 cytokine release syndrome (CRS) occurred in 80% of patients, with no cases of ≥grade 2 CRS. No immune effector cell-associated neurotoxicity syndrome (ICANS) or other neurotoxic reactions were observed.
More news about: IASO Bio
Oct 16, 2025, 08:30 ET Dominari Securities Raises Over $1.4 Billion Year-to-Date in Support of American Innovation and Entrepreneurship
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Oct 16, 2025, 08:00 ET TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of
More news about: Johnson & Johnson
Oct 15, 2025, 11:30 ET MLG CAPITAL PRINCIPAL AND SENIOR VICE PRESIDENT RYAN MUELLER SELECTED BY GLOBEST. AS A 2025 INFLUENCER IN MULTIFAMILY
FINRA/SIPC . Its Form CRS may be found
More news about: MLG Capital
Oct 14, 2025, 12:00 ET Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
the phase I/II study. Among 54 patients treated at 4.0 mg/kg or above and reaching tumor assessment, 19 partial responses (PRs) or complete responses (CRs) were observed. 7 patients with esophageal cancer (EC) were enrolled at 4.0 mg/kg or above and achieved an objective response rate (ORR) of 42.9% and
More news about: Mabwell
Oct 10, 2025, 11:48 ET HEMI AND DOMINARI SECURITIES TO DEVELOP DIGITAL ASSET TREASURY AND ETF PLATFORMS
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Hemi
Oct 09, 2025, 08:00 ET Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.